Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. - Wikidata - wikimedia - TriplyDB

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

http://www.wikidata.org/entity/Q34695408

about

Improved endpoints for cancer immunotherapy trials Gene Therapy Applications to Cancer Treatment Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay A modified human ELISPOT assay to detect specific responses to primary tumor cell targets T-cell clonotypes in cancer The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT Immune regulation of human herpesviruses and its implications for human transplantation Cancer vaccines Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Prostate cancer as a model for tumour immunotherapy.Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients Advances in prophylactic cancer vaccine research.Preamble to the 2015 SITC immunotherapy biomarkers taskforce Clinical application of dendritic cells in cancer vaccination therapy.SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery Dendritic cell vaccination and immunostimulation in advanced melanoma.Peptide-based vaccines for cancer immunotherapy.Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Immunotherapy in non-renal carcinomas.DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells Toward the harmonization of immune monitoring in clinical trials: quo vadis?Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.Therapeutic lymphoma vaccines: importance of T-cell immunity.ABO blood type correlates with survival on prostate cancer vaccine therapy Cutaneous melanomas of the eyelid.Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.

P2860

Q24603112-6B8FCE9B-EA42-40C5-BB30-30EC3B068CEC Q24792808-3C763E52-A689-4412-9239-4C608E47DB1B Q24800129-9F6A4D67-1DAA-4467-A48A-FCEBB29DCB55 Q24800412-852237DF-CF1A-4308-908E-65F5A6E11A9A Q24803891-33F829B1-01A6-47AB-8BC5-FAA6B2BC2C1E Q24806953-5B8E2D7E-8325-43A7-AEAB-CD71F5EB75BA Q24815388-6CA75952-9F4B-417F-A668-DC09C3C1DBC0 Q26992146-92282204-18DE-4455-A99D-D25C7D0576D1 Q27024438-E1FB3B28-47BB-4375-B41B-1B381BC6A08B Q28730430-D0BAE677-E8BF-45A0-805A-423988705CD2 Q28744503-784919C8-4316-4BD6-9ECE-283B31DD09C3 Q30370848-0AFE25B0-2C66-458D-A7EB-75EC07EE0AE0 Q30438965-F661F241-4408-4E6E-884C-C53C7FA6371D Q30440347-0BE4C2B9-4C4E-41C2-B0D1-E80873B72DD3 Q30444086-1643C8E6-05B1-4EF8-B4D5-CC3241B939A3 Q33248961-44B0D8CD-33CA-4FE8-9872-25ED19C23CEA Q33501195-36A78899-1243-4E18-9D6C-DC8CE250D50B Q34090155-303599C7-6C4F-48CC-B9F9-4AA7AD2B833D Q34434814-A77EB1F9-7988-4CF9-B130-E00C55CB80A7 Q34617770-DE98B2EA-5B37-45C0-9BC9-2D9C88D0D59E Q34635795-637F5DA6-D45C-4B57-BC58-C23B82AC9055 Q34856875-7167E018-8FA9-4EA3-BE55-9EB43781671E Q35021619-8602373C-C5EF-4A09-8CA4-020A942933F1 Q35204975-AF8D4D98-6B55-4F81-94EC-27EEC5DB05F8 Q35212166-B67A2A57-4097-4EB0-90E1-085F40D9343B Q35219339-2414B9A0-2736-4EF3-82DB-C501E1E3354D Q35298744-93F6BF87-D9EC-4F2F-9CAF-C4E8CAE1592E Q35623395-40ECF1C0-A43B-40F3-855D-ACAB3AC21E94 Q35681508-D10102BF-193F-45C9-82A8-08A07AAC8835 Q35751259-92477713-7037-415A-AAB3-22CEA3929103 Q35775916-2016DA37-1350-4909-AAC0-C837C76B324B Q35826392-80407BB0-804C-474B-9F89-23601C9498EE Q36112645-EB7321FC-7216-4E95-9672-181C52319D22 Q36116566-243BAA3E-8751-4F8A-BAE2-E633F17EC890 Q36293565-81FA637E-551C-4D6E-9A7A-DC5AEF788EC4 Q36353361-6E31FFA2-ACB3-4A02-81E9-4B85D6E7EDCB Q36530231-C6DC322F-9BCD-4253-BCBE-662B89F40F44 Q36544831-4D2871C8-2CB5-438B-BEFF-CFBB6DBE77FA Q36567113-7AE8F1BC-890C-4D1F-8DBE-F817E97EB1FE Q36611097-83B321FC-9C3A-4B36-9F78-C6F5D89CB69A

P2860

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

http://www.wikidata.org/entity/Q34695408

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@ast

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@en

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@nl

type

label

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@ast

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@en

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@nl

prefLabel

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@ast

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@en

Immunologic monitoring of canc ...... ociety for Biological Therapy.

@nl

P1433

Q34695408-836AFAAC-32E0-402B-A613-BA411CBCBEDC

P1476

Q34695408-2E57F66D-D03B-4112-87B6-428AF87F3AA0

P2093

Q34695408-0AF61CB1-8F32-48B2-B4AA-07480B4FD910

Q34695408-39B0CEFE-7E16-46EB-8D79-61CF92586A5F

Q34695408-46F55CB4-E981-4C4C-8B44-22AAD493E1DF

Q34695408-5C426F26-F72D-47C8-8FF8-A231D3FC5EDB

Q34695408-640FACDC-698E-483A-9A48-8EFC47E4DAEF

Q34695408-72C16232-0615-4F2A-8E0E-D475443F76BB

Q34695408-72F2FB08-202B-491F-B6D1-430E974ABAFE

Q34695408-83F5ADCF-FF66-405C-AD0D-89E965B41698

Q34695408-95A7393D-A24D-42B1-BE35-998F5BFE6505

Q34695408-99488165-0546-4ACD-B606-638140F2900B

P304

Q34695408-CFB9BBE9-CCC7-49FB-8077-A611476F9769

P31

Q34695408-B2E314E0-F4A4-4D08-9F6A-06BA15CDCF05

P356

Q34695408-5FFD82A3-FA82-4801-878B-FC5BFF573B5E

P433

Q34695408-9A69660A-52A9-4A6E-A3D0-583CF914D718

P478

Q34695408-53DAA395-43D3-40AE-AB20-F6AAEF32D6B0

P50

Q34695408-70D4E8A9-8167-4290-A191-5C2C890F40DC

Q34695408-A2461A1A-FAA8-473E-878C-53B556D9F5E3

Q34695408-DF691611-FF80-46DC-A8A2-4F6B693C729E

P577

Q34695408-EE2EADC1-343A-4DDD-8A67-A40853F8DE0F

P5875

Q34695408-559947E2-77E8-43C6-B286-A466CD7F68C2

P698

Q34695408-D4FF272B-0C3B-41BF-9C55-7DC35B8DEC87

P921

Q34695408-6400E16E-220C-4784-97C7-38BBD0E86690

P356

00002371-200203000-00001

P1433

Journal of Immunotherapy

P1476

Immunologic monitoring of canc ...... Society for Biological Therapy

@en

P2093

Alexandra Worobec

http://www.w3.org/2001/XMLSchema#string

Carmen Scheibenbogen

http://www.w3.org/2001/XMLSchema#string

Dmitry I Gabrilovich

http://www.w3.org/2001/XMLSchema#string

Franceso Marincola

http://www.w3.org/2001/XMLSchema#string

James H Finke

http://www.w3.org/2001/XMLSchema#string

Jeff Schlom

http://www.w3.org/2001/XMLSchema#string

Jeffrey Weber

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Mary L Disis

http://www.w3.org/2001/XMLSchema#string

Michael B Atkins

http://www.w3.org/2001/XMLSchema#string

P304

97-138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002371-200203000-00001

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Walter J. Storkus

Herbert Kim Lyerly

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11300914

http://www.w3.org/2001/XMLSchema#string

P698

12074049

http://www.w3.org/2001/XMLSchema#string

P921